|
Haemonetics Corporation (NYSE: HAE) |
|
Haemonetics Corporation
HAE's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Haemonetics's sales fell
by -3.74 % in the fourth quarter of 2025 from the same quarter a year ago.
Ranking at No. 2166
Medical Equipment & Supplies industry recorded
deterioration of revenues by -0.37 %
Haemonetics's net income grew by 184.68 % in fourth quarter of 2025 year on year, above company average,
• More on HAE's Growth
|
|
Haemonetics current PE on trailing twelve month basis is above Medical Equipment & Supplies industry average.
Haemonetics PEG ratio is at 0.47
Company is currently trading with Price to Cash flow multiple of 27.74 in trailing twelve-month period. |
Company |
21.11 |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 2.61.
Medical Equipment & Supplies industry's Price to Sales ratio is at 4.06.
• More on HAE's Valuation
|
|
|
|
|
Haemonetics current PE on trailing twelve month basis is above Medical Equipment & Supplies industry average.
Haemonetics PEG ratio is at 0.47
Company is currently trading with Price to Cash flow multiple of 27.74 in trailing twelve-month period. |
Company |
21.11 |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 2.61.
Medical Equipment & Supplies industry's Price to Sales ratio is at 4.06.
Haemonetics Price to Book Ratio is at 4.32 higher than Industry Avg. of -499.24, and higher than S&P 500 Avg. of 0.01
• More on HAE's Valuation
|
|
HAE's Profitability Comparisons
|
Haemonetics achieved increase in profitability, due to cost control. Operating Margin grew in fourth quarter of 2025 to 21.55 % from 16.98 % in III. Quarter.
Haemonetics net profit margin of 17.51 % is currently ranking no. 14 in Medical Equipment & Supplies industry, ranking no. 63 in Healthcare sector and number 773 in S&P 500.
Profitability by Segment |
Plasma |
52.34 % |
Blood Center |
38.11 % |
Hospital |
43.06 % |
Total |
10.79 % |
|
|
Haemonetics achieved increase in profitability, due to cost control. Operating Margin grew in fourth quarter of 2025 to 21.55 % from 16.98 % in III. Quarter.
Haemonetics net profit margin of 17.51 % is currently ranking no. 14 in Medical Equipment & Supplies industry, ranking no. 63 in Healthcare sector and number 773 in S&P 500.
• More on HAE's Key Ratios
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com